Semaphorin 7A in circulating regulatory T cells is increased in autosomal-dominant polycystic kidney disease and decreases with tolvaptan treatment.

Yashang LeeKatrina Lehmann BlountFeng DaiSiobhan ThompsonJonathan Kaufman ScherSherrie BittermanMadeline DroherErica L HerzogGilbert MoeckelAnil KarihalooNeera K Dahl

Published in: Clinical and experimental nephrology (2018)

SEMA7A shows potential as both a therapeutic target in mammalian kidney fibrosis and as a marker of inflammation in ADPKD patients. SEMA7A expression was lower after tolvaptan treatment, which may reflect drug efficacy.

Keyphrases

polycystic kidney disease
regulatory t cells
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
dendritic cells
immune response
emergency department
patient reported outcomes
risk assessment
replacement therapy
adverse drug
smoking cessation